Suzhou Zelgen Biopharmaceuticals Co.,ltd

This phase 2 trial is testing whether adding an experimental immunotherapy drug called ZG005 to standard chemotherapy (gemcitabine and cisplatin) can help people with advanced gallbladder cancer. About 60 participants will receive either the combination or standard treatment. The…

This study tests a new drug called ZG006 combined with standard immunotherapy (with or without chemotherapy) as a first treatment for people with extensive-stage small cell lung cancer. About 100 adults aged 18-75 with good performance status are being recruited. The main goals a…

This study tests a new drug called ZGGS34 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and second, testing how well the drug works alone or with chemotherapy in patients whose tumors have…

This study tests two experimental drugs, ZG006 and ZG005, given together by IV in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial aims to see if the combination is safe and can shrink tumors. About 350 adults aged 18 to 70 are being recruited at…

This study tests a new combination of two drugs—ZG005 (given by IV) and gecacitinib (taken as a pill)—in 50 adults with advanced non-small cell lung cancer that has not responded to prior PD-1/L1 therapy. The goal is to see if the combination is safe and can shrink tumors. Partic…

This study tests an experimental drug called ZG006 in people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments or cannot tolerate them. The main goals are to find a safe dose and check for side effects. About 54 adults aged 18 to 75 w…

This study tests two experimental drugs, ZG005 and gecacitinib (with or without bevacizumab), in 120 women with advanced cervical cancer. The goal is to see if the combination is safe and can shrink tumors. Participants must be 18-75 and have a confirmed diagnosis of advanced cer…

This Phase 3 trial compares a new drug called ZG006 with standard chemotherapy in 420 people whose small cell lung cancer has returned. The main goal is to see if ZG006 helps patients live longer. Participants will receive either ZG006 or one of several chemo options chosen by th…

This study tests a combination of two drugs, ZG005 and gecacitinib, in 60 adults with relapsed or refractory lymphoma (cancer of the lymph system). The first part finds a safe dose; the second part checks if the combo shrinks tumors. Participants must have confirmed lymphoma that…

This study tests a new drug called ZGGS18 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 222 participants will take part in this early-phase trial.

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the…

This study tests a new biologic drug called ZG006 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The trial has two parts: first, finding a safe dose (Phase 1), then testing how well it shrinks tumors (Phase 2). About 265 participants will receive ZG00…